Literature DB >> 330776

Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.

A I Braude, E J Ziegler, H Douglas, J A McCutchan.   

Abstract

Antiserum to the core glycolipid of gram-negative bacteria was prepared by immunization of rabbits with vaccine composed of killed cells of the uridine diphosphate galactose-deficient mutant (J5) of Escherichia coli O:111. Antiserum to J5 not only prevented death of animals from endotoxin but also prevented the local and generalized Shwartzman reactions. Antiserum to endotoxin also prevented renal cortical necrosis and disseminated intravascular coagulation during the evolution of the generalized Shwartzman reaction. Antiserum to be J5 mutant was successful in the treatment of overwhelming bacteremia produced by other gram-negative bacteria; in addition to bacteremia cause by coliform organism, antiserum to J5 was dramatically effective in treatment of bacteremia due to Pseudomonas aeruginosa. One injection of rabbit antiserum to J5 improved the survival rate from 15% in controls to 59% in treated animals (P less than 0.002). Active immunization with J5 vaccine was even more effective against pseudomonas bacteremia: such immunization improved the survival rate from 13% in controls to 92% in vaccinated rabbits. Since an antiserum effective against the J5 mutant of E. coli can be prepared safely in human subjects, such immunotherapy should be considered for patients with gram-negative bacteremia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 330776     DOI: 10.1093/infdis/136.supplement.s167

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

Review 1.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

2.  Cross-reactivity of monoclonal antibodies against lipopolysaccharides of gram-negative bacteria.

Authors:  J de Jongh-Leuvenink; A S Bouter; J H Marcelis; J Schellekens; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

Review 3.  Immunotherapeutic advances in the treatment of gram-negative bacterial sepsis.

Authors:  D L Dunn
Journal:  World J Surg       Date:  1987-04       Impact factor: 3.352

4.  Prevention of fever and gram negative infection after open heart surgery by antiendotoxin.

Authors:  R Freeman; F K Gould
Journal:  Thorax       Date:  1985-11       Impact factor: 9.139

5.  Protection of mice against the lethal toxicity of a lipopolysaccharide (LPS) by immunization with anti-idiotype antibody to a monoclonal antibody to lipid A from Eikenella corrodens LPS.

Authors:  T Kato; I Takazoe; K Okuda
Journal:  Infect Immun       Date:  1990-02       Impact factor: 3.441

6.  Role for endotoxin in the leukocyte infiltration accompanying Escherichia coli inflammation.

Authors:  A C Issekutz; S Bhimji
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

Review 7.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Immunization against bacteria- and endotoxin-induced hypotension.

Authors:  A M Abdelnoor; A G Johnson; A Anderson-Imbert; A Nowotny
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

9.  Turbidimetric method for quantifying serum inhibition of Limulus amoebocyte lysate.

Authors:  T J Novitsky; P F Roslansky; G R Siber; H S Warren
Journal:  J Clin Microbiol       Date:  1985-02       Impact factor: 5.948

10.  Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity.

Authors:  W C Bogard; D L Dunn; K Abernethy; C Kilgarriff; P C Kung
Journal:  Infect Immun       Date:  1987-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.